- Home
- EVAX vs GIGM Comparison
EVAX vs GIGM Comparison
Compare EVAX & GIGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- GIGM
- Stock Information
- Founded
- EVAX 2008
- GIGM 1998
- Country
- EVAX Denmark
- GIGM Taiwan
- Employees
- EVAX N/A
- GIGM N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- GIGM Computer Software: Programming Data Processing
- Sector
- EVAX Health Care
- GIGM Technology
- Exchange
- EVAX Nasdaq
- GIGM Nasdaq
- Market Cap
- EVAX 16.3M
- GIGM 16.0M
- IPO Year
- EVAX 2021
- GIGM 2000
- Fundamental
- Price
- EVAX $2.53
- GIGM $1.50
- Analyst Decision
- EVAX Strong Buy
- GIGM
- Analyst Count
- EVAX 3
- GIGM 0
- Target Price
- EVAX $33.33
- GIGM N/A
- AVG Volume (30 Days)
- EVAX 6.8M
- GIGM 6.8K
- Earning Date
- EVAX 03-26-2025
- GIGM 03-28-2025
- Dividend Yield
- EVAX N/A
- GIGM N/A
- EPS Growth
- EVAX N/A
- GIGM N/A
- EPS
- EVAX N/A
- GIGM N/A
- Revenue
- EVAX $3,295,000.00
- GIGM $3,085,000.00
- Revenue This Year
- EVAX $9,039.73
- GIGM N/A
- Revenue Next Year
- EVAX $1.47
- GIGM N/A
- P/E Ratio
- EVAX N/A
- GIGM N/A
- Revenue Growth
- EVAX N/A
- GIGM N/A
- 52 Week Low
- EVAX $2.22
- GIGM $1.23
- 52 Week High
- EVAX $22.05
- GIGM $1.80
- Technical
- Relative Strength Index (RSI)
- EVAX 40.91
- GIGM 42.75
- Support Level
- EVAX $2.43
- GIGM $1.47
- Resistance Level
- EVAX $2.80
- GIGM $1.54
- Average True Range (ATR)
- EVAX 0.31
- GIGM 0.03
- MACD
- EVAX 0.07
- GIGM -0.00
- Stochastic Oscillator
- EVAX 16.94
- GIGM 44.44
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About GIGM GigaMedia Limited
GigaMedia Ltd is a publisher of online games. It has only one reportable segment, Digital Entertainment service. Digital Entertainment service business operates a portfolio of online games, mainly targeting online game players across Europe, and Asia, including Greater China and Southeast Asia. The company's portfolio of online games includes predominantly PC-based, non-cash gambling, or casino casual games, including MahJong and various card and table games. The company's product lines include MahJong, AkaSeka, Yume 100, Fun Vegas, and others. The company operates in Taiwan and Hong Kong.